Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Advanced Endometrial Carcinoma Published in the New England Journal of Medicine Posted on January 20, 2022 By Phase 3 Results of KEYNOTE-775/Study 309 Trial KEYTRUDA Plus LENVIMA in Advanced Endometrial Carcinoma Published in New England Journal of Medicine News